Zoetis' lokivetmab OK'd in Europe

|About: Zoetis (ZTS)|By:, SA News Editor

The European Commission approves Zoetis' (NYSE:ZTS) Cytopoint (lokivetmab) for veterinary use to treat atopic dermatitis in dogs weighing at least three pounds. It is the first monoclonal antibody approved in the EU for this indication.

Cytopoint, administered once per month via injection, binds to canine interleukin-31, a protein that plays a key role in triggering itch in man's best friend.